diabetes-cure
(2)
Imagine Pharma
Imagine Pharma is a Pittsburgh biotechnology company built around IMG-1, a novel polypeptide its founder discovered in a tea plant from his native Vietnam. From that single molecule the company runs three platforms - Oral Delivery (making injectable biologics swallowable), Therapeutics, and Regenerative Medicine - with first-in-class programs aimed at curing type 1 diabetes, accelerating diabetic wound healing, and making injections obsolete. Alongside its pipeline, Imagine operates an NIH-approved islet isolation center that has completed dozens of clinical islet cell procedures for major U.S. hospital systems.
Ngoc Thai
Ngoc L. Thai, MD, PhD is a transplant surgeon turned biotech founder who built one of the world's largest pancreas programs before chasing a hunch from a cup of his uncle's tea. As founder, co-CEO and CMO of Pittsburgh-based Imagine Pharma, he is developing IMG-1, a polypeptide first isolated from a Vietnamese tea plant, into therapies that coax insulin-producing islet cells to multiply and regenerate. The company raised a $32.5M Series A in October 2023 to advance IMG-1 across oral delivery, therapeutics, and regenerative medicine platforms aimed at type 1 diabetes, wound healing, and other underserved conditions.